Investors in Irish financier Cathal Friel’s drug research venture hVIVO are set for a payback after double-digit revenue growth last year.
Mr Friel is the founder of Raglan Capital, which specialises in creating in-house pharmaceutical companies that it quickly takes public.
The Dublin and London-listed hVIVO, formerly Open Orphan, expects to report full-year revenues of £50.6m (€57.3m) for 2022, up 30pc year on year.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.